Multimodal Imaging Evaluation and Prognostic Analysis of Cardiac Allograft Vasculopathy in Heart Transplantation
NCT ID: NCT04966988
Last Updated: 2021-07-19
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
NOT_YET_RECRUITING
1000 participants
OBSERVATIONAL
2021-08-01
2026-08-01
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Research on Patients With Heart Transplantation
NCT04921774
Magnetocardiography as a Non-Invasive Tool for Detecting Tissue Rejection in Heart Transplant Patients
NCT00169936
Cardiac MRI and Cardiac Allograft Rejection
NCT04311346
Diagnosis and OutcoMes evaluAtIoN of Multicenter Patients With HFpEF Using Multimodality Imaging
NCT04602338
Cardiac Magnetic Resonance Imaging (CMRI) for Detection of Cardiac Transplant Rejection
NCT01136135
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
CAV 0(Not significant)
No detectable angiographic lesion
No interventions assigned to this group
CAV 1 (Mild)
Angiographic left main (LM) \<50%, or primary vessel with maximum lesion of \<70%, or any branch stenosis \<70% (including diffuse narrowing) without allograft dysfunction
No interventions assigned to this group
CAV 2 (Moderate)
Angiographic LM \<50%; a single primary vessel≥70%, or isolated branch stenosis ≥70% in branches
No interventions assigned to this group
CAV 3 (Severe)
Angiographic LM≥50%, or two or more primary vessels ≥70% stenosis, or isolated branch stenosis≥70%in all 3 systems; or CAV1 or CAV2 with allograft dysfunction (defined as LVEF≤45% usually in the presence of regional wall motion abnormalities) or evidence of significant restrictive physiology
No interventions assigned to this group
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
18 Years
80 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Second Affiliated Hospital, School of Medicine, Zhejiang University
OTHER
Shanghai Zhongshan Hospital
OTHER
Henan Provincial People's Hospital
OTHER
Wuhan Asia Heart Hospital
OTHER
Guangdong Provincial People's Hospital
OTHER
Xie Mingxing
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Xie Mingxing
MD, PhD,FACC, FAHA, FASE
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Li Zhang, PhD
Role: PRINCIPAL_INVESTIGATOR
Department of Ultrasound, Union Hospital, Wuhan, China
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2021 V 1.0
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.